We suggest you to use BioLight Life Sciences fundamental analysis to see if markets are presently mispricing the company. In plain English you can use it to find out if BioLight Life Sciences is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found twenty-seven available fundamental indicators for BioLight Life Sciences Ltd which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all BioLight Life Sciences fundamentals including its Gross Profit, Net Income and the relationship between Revenue and EBITDA . Use BioLight Life to enhance returns of your portfolios. The stock experiences normal upward fluctuation. Check odds of BioLight Life to be traded at S1543.5 in 30 days.
BioLight Life Company Summary
BioLight Life competes with Kamada Ltd, Compugen Ltd, BioTime, Clal Biotechnology, and Pluristem Therapeutics. BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions comprising glaucoma, dry eye syndrome, and age-related macular degeneration. BioLight Life Sciences Ltd. was founded in 2005 and is based in Tel Aviv, Israel. BioLight Life operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
BioLight Life Sciences Ltd is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies reporting about 0.46 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for BioLight Life Sciences Ltd is roughly 2.16
BioLight Life Market Fundamentals
BioLight Life Financial Distress Probability
Chance of Financial Distress
BioLight Life Sciences Ltd has less than 41 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info